Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
Authors:
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 11
Abstract
Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human malignancies. For hematologic malignancies, approximately one-third of anaplastic large-cell non-Hodgkin’s lymphomas were found to express a fusion between NPM1 and the catalytic domain of anaplastic lymphoma receptor tyrosine kinase. About 50–60% of acute myeloid leukemia patients with normal karyotype carry NPM1 mutations, which are characterized by cytoplasmic dislocation of the NPM1 protein. Nevertheless, NPM1 is overexpressed in various hematologic and solid tumor malignancies. NPM1 overexpression is considered a prognostic marker of recurrence and progression of cancer. Thus, NPM1 abnormalities play a critical role in several types of hematologic malignancies. This has led to intense interest in the development of an NPM1 targeting strategy for cancer therapy. The aim of this review is to summarize present knowledge on NPM1 origin, pathogenesis, and therapeutic interventions in hematologic malignancies.Keywords
Funding Information
- Natural Science Foundation of Fujian Province (2015J05152)
- Cooperation Project of University and Industry (2017Y4005)
- Construction Project of Fujian Medical Center of Hematology (Min201704)
- National Natural Science Foundation of China (81500158, 81470326)
- Joint Funds for the Innovation of Science and Technology in Fujian Province (2016Y9029, 2016Y9032)
- Joint Research Project of Health and Education in Fujian province (WKJ2016-2-06)
- the Program of New Century Excellent Talents in Fujian Province University (2016B032)
This publication has 130 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Nucleophosmin Interacts with FOXM1 and Modulates the Level and Localization of FOXM1 in Human Cancer CellsJournal of Biological Chemistry, 2011
- Nucleophosmin and its complex network: a possible therapeutic target in hematological diseasesOncogene, 2011
- A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemiasBlood, 2010
- Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various LevelsJournal of Biological Chemistry, 2010
- Acetylated NPM1 Localizes in the Nucleoplasm and Regulates Transcriptional Activation of Genes Implicated in Oral Cancer ManifestationMolecular and Cellular Biology, 2009
- Structural Consequences of Nucleophosmin Mutations in Acute Myeloid LeukemiaJournal of Biological Chemistry, 2008
- Pathobiology of ALK+ anaplastic large-cell lymphomaBlood, 2007
- Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survivalProceedings of the National Academy of Sciences, 2007
- Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear ExportMolecular and Cellular Biology, 2006